Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.92
-0.26 (-3.18%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Xilio Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Net Income
-35.04-58.24-76.4-88.22-75.8
Upgrade
Depreciation & Amortization
1.541.641.91.851.5
Upgrade
Loss (Gain) From Sale of Assets
-0000.02
Upgrade
Stock-Based Compensation
6.946.437.388.424.96
Upgrade
Other Operating Activities
-3.56-0.160.220.38
Upgrade
Change in Accounts Receivable
-5----
Upgrade
Change in Accounts Payable
0.151.53-2.060.49-2.82
Upgrade
Change in Unearned Revenue
27.8832.78---
Upgrade
Change in Other Net Operating Assets
2.1-2.520.411.52-8.99
Upgrade
Operating Cash Flow
-4.99-18.38-68.62-75.72-80.75
Upgrade
Capital Expenditures
-0.52-0.04-0.49-1.87-1.1
Upgrade
Investing Cash Flow
-0.52-0.04-0.49-1.87-1.1
Upgrade
Long-Term Debt Issued
----0.98
Upgrade
Long-Term Debt Repaid
--3.38-6.75-0.09-1.09
Upgrade
Net Debt Issued (Repaid)
--3.38-6.75-0.09-0.11
Upgrade
Issuance of Common Stock
87.7832.580.20.02116.64
Upgrade
Other Financing Activities
-----0.75
Upgrade
Financing Cash Flow
87.7829.2-6.55-0.07260.67
Upgrade
Net Cash Flow
82.2710.78-75.66-77.66178.82
Upgrade
Free Cash Flow
-5.51-18.41-69.11-77.59-81.85
Upgrade
Free Cash Flow Margin
-12.59%-290.26%---
Upgrade
Free Cash Flow Per Share
-1.22-4.82-35.19-39.66-204.40
Upgrade
Cash Interest Paid
-0.060.570.560.49
Upgrade
Levered Free Cash Flow
8.03-16.23-42.32-45.9-52.31
Upgrade
Unlevered Free Cash Flow
8.03-16.23-41.88-45.4-51.94
Upgrade
Change in Working Capital
25.1331.78-1.662-11.8
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.